Moreover, targeting C-X3-C motif chemokine ligand 1 (CX3CL1) and C-X3-C motif chemokine receptor 1 (CX3CR1), which are involved in mobilization of tumor-promoting macrophages, can also be an effective therapeutic intervention with possible effects in disrupting the recruitment of immune cells in preclinical models [32]. This evidence concerns the gene CX3CL1 and neoplasm.